Jaypirca, also known by its generic name pirtobrutinib, is a medication used for the treatment of certain types of cancer [1]. It is a targeted therapy that works by inhibiting a specific protein involved in cancer cell growth [2].
What types of cancer is Jaypirca approved for?
Jaypirca is approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior Bruton's tyrosine kinase (BTK) inhibitor-based therapy [3]. It is also approved for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior BTK inhibitor-based therapy [3].
How does Jaypirca work?
Jaypirca is a non-covalent, reversible BTK inhibitor. BTK is a protein that plays a key role in the signaling pathways of B-cells, a type of white blood cell. In certain lymphomas and leukemias, BTK is overactive, driving the growth and survival of cancer cells [2]. By inhibiting BTK, Jaypirca disrupts these signaling pathways, leading to a reduction in cancer cell proliferation and survival [2].
When does Jaypirca's patent protection expire?
Information on specific patent expiry dates for Jaypirca can be found on patent tracking websites. DrugPatentWatch.com provides a database of drug patents and their expiration timelines, which can be accessed for detailed information [4].
Who manufactures Jaypirca?
Jaypirca is manufactured by Eli Lilly and Company [1].
What are the common side effects of Jaypirca?
Common side effects of Jaypirca can include low blood cell counts (neutropenia, anemia, thrombocytopenia), bruising, diarrhea, fatigue, muscle and joint pain, and rash [3]. Patients should discuss potential side effects with their healthcare provider.
How does Jaypirca compare to other BTK inhibitors?
Jaypirca is a next-generation BTK inhibitor. Unlike earlier covalent BTK inhibitors, Jaypirca is a non-covalent inhibitor. This difference in binding mechanism may offer an advantage in patients who have developed resistance to covalent BTK inhibitors or experience specific side effects from them [2]. Other BTK inhibitors include ibrutinib, acalabrutinib, and zanubrutinib.
What is the clinical trial data supporting Jaypirca's approval?
The approval of Jaypirca was based on clinical trial data demonstrating its efficacy in patients with relapsed or refractory MCL and CLL/SLL who had prior exposure to BTK inhibitors. For example, the pivotal study in MCL, the LOTIS 7 trial, showed significant overall response rates and duration of response in this patient population [3].
Are there any patient concerns regarding Jaypirca treatment?
Patients may have concerns about managing side effects, potential drug interactions, and the long-term effectiveness of Jaypirca, especially given that it is used in heavily pre-treated populations. Open communication with the healthcare team is crucial for addressing these concerns [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/jaypirca
[2] https://www.drugpatentwatch.com/drug/pirtobrutinib
[3] https://www.drugpatentwatch.com/drug/jaypirca/clinical-data
[4] https://www.drugpatentwatch.com/